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nosis)) AND discordance[Title/Abstract]) AND lymphoma)) OR ((lymphoma[Title]) 
AND pathology[Title]). The pooled major discordance frequency was calculated 
using Neyeloff, Fuchs and Moreira’s Excel random effects model (2012). Weighted 
averages using a random-effects model are reported with 95% confidence intervals 
with continuity correction. Results: Eight (8) articles evaluating and differentiat-
ing minor and major second-opinion discordance in lymphoma diagnosis were 
included in this study. Major discordance is defined as diagnostic discrepancy 
between the preliminary or final diagnosis and second-opinion review that is 
determined by the study authors could have an impact on patient management. 
The proportion of discordance that was major ranged from 4.27% to 20.00%. The 
pooled proportion of major discordance was 9.10% (95% CI 5.86%-12.35%) in a 
pooled sample of 5,322 lymphoma patients. Only 1 study, a published abstract, 
analyzed the actual patient impact of discordant pathological results through 
chart review, determining 2.9% of patients were over-treated, under-treated, had 
significant change in treatment or incorrect treatment due to diagnostic error 
(Kukreti et al., 2006). ConClusions: Diverse methodologies led to considerably 
variable estimates; however, this meta-analysis revealed that an estimated 9.10% 
of lymphoma diagnoses could be incorrect to the point of impacting patient treat-
ment management.
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objeCtives: Currently various diagnostic pathways for incidentally detected pul-
monary nodules are used and it is not clear which diagnostic pathway should be 
used to potential lung cancer. An early diagnosis of a possible malignancy in the 
lung is important in order to increase the survival chance of the patient. In this study 
the regular used Fleischner Recommendations are compared with a software based 
volume doubling time(VDT) technique. Methods: A model of the two possible 
diagnostic pathways is developed and built in R. The used incidence rates of pulmo-
nary nodules and lung cancer are obtained from literature. The primary endpoint is 
the incidence rate of lung cancer after one year. Secondary endpoints are the test 
results of the diagnostic pathways. Ten thousand patiens were included in order to 
decrease bias and increase precision of the model. Results: Diagnosis with help 
of VDT led to a lower rate of false postives and false negatives, compared to the 
Fleischner Recommendations. Furthermore, € 188.394,66 was saved in the simula-
tion when VDT was used. The sensitivity of VDT could decrease with 7 percent in 
order to be as good as Fleischner Criteria, and was still cheaper. ConClusions: The 
replacement of the Fleischner Recommendation by software based VDT can lead 
to a decrease in false positives and false negatives. Since the total costs of VDT are 
lower than the costs of the Fleischner Recommendation also a reduction in health 
care costs is possible. However, since this was an early-stage research more direct 
evidence should be collected in the future.
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objeCtives: To understand and quantify the clinical and economic impact of an 
automated, on-demand diagnostic test versus current diagnostic tests, for hep-
arin-induced thrombocytopenia (HIT). Methods: A mixed methods study com-
bining a literature review with primary research. The literature review searched 
multiple databases to identify data on test performance, clinical and economic 
data. Semi-structured interviews (n= 4) provided insight into current practice and 
challenges faced, validated by a larger survey (n= 90). Two flow diagrams modelling 
a hypothetical cohort of 1000 patients were used to calculate the clinical and cost 
impact of automated, on-demand testing. Results: The automated, on-demand 
test had comparable or lower sensitivity, and a higher specificity than other avail-
able tests. Clinical data and survey findings indicate that the specificity of the most 
widely used antibody tests (ELISA) is suboptimal. The survey revealed that half of 
patients are speculatively switched off of heparin and onto replacement therapy 
based on clinical assessment alone, rather than based on clinical assessment and 
diagnostic test results as per guideline recommendations. Speculative treatment 
is driven by test turnaround time of > 24 hours for > 50% of respondents. The cost 
model indicated that the cost of replacement therapy whilst awaiting tests results 
of > 24 hours’ turnaround time was between $7215 and $31268. Automated, on-
demand antibody testing and switching patients off heparin based on test results 
reduced this cost to between $2737 and $13092. ConClusions: Automated, on-
demand HIT antibody testing could enable physicians to use timely diagnostic test 
results with better specificity than current tests to make treatment decisions. This 
could potentially enable earlier treatment of HIT to reduce complications such as 
extended hospitalisation and death, thus improving clinical outcomes and reduc-
ing costs. Also, earlier informed treatment decisions could yield pathway cost 
reductions through reducing the use of replacement therapies in non-confirmed 
and false positive cases.
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have comparable cycles for both strategies a three-year time horizon was used 
for cost comparison. Total screening costs were 26% lower for HPV genotyping 
and only 21% higher for treatment costs, resulting in total savings of 1.6 million 
over cytology. ConClusions: Compared to cytology, incorporation of cobas HPV 
genotyping test as primary screening for CxCa at IMSS represents during the 
first-cycle potential savings of 10% as an improvement in clinical benefits, such 
as reduction in the incidence and mortality due to CxCa.
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objeCtives: The fraction of exhaled nitric oxide (FeNO), a marker of eosinophilic 
inflammation, may be a useful diagnostic test in asthma. This systematic review 
aimed to identify and synthesise evidence relating to the diagnostic accuracy of 
FeNO for asthma. Methods: Systematic searches of nine key biomedical data-
bases and trial registers (including MEDLINE, EMBASE , the Cochrane library and 
clinicaltrials.gov) were carried out to November 2014. Records were considered by 
one reviewer and included if they: recruited patients presenting with the symp-
toms of asthma; used a single set of criteria (i.e. not case-control); measured 
FeNO in accordance with American Thoracic Society guidelines, 2005 (off-line 
measurements excluded); reported/allowed calculation of true positive, true nega-
tive, false positive and false negative patients as classified against any reference 
standard. Study quality was assessed using QUADAS II. Data was extracted by one 
reviewer using a standardised form and checked by a second. Meta-analysis was 
planned where clinical study heterogeneity allowed. Rule-in and Rule-out uses 
of FeNO were considered. Results: 4865 records were identified and 32 studies 
were included. 5 studies recruited children and/or adolescents, and 27 studies 
recruited mixed ages or adults. Studies were sub-grouped by study characteris-
tics. Heterogeneity precluded meta-analysis. Cut-off values for the best sum of 
sensitivity and specificity varied from 12ppb to 55ppb, being generally lower in 
children. Results varied, but the highest sum of sensitivity and specificity was 
reported for patients with chronic cough using a reference standard of airway 
reversibility testing (sensitivity 90% and specificity 85%). 100% sensitivity or 100% 
specificity were reported by some studies indicating potential use as a rule-in or 
rule-out strategy. ConClusions: FeNO has variable diagnostic accuracy even 
within subgroups of studies with similar characteristics. However, FeNO could 
be informative within a diagnostic pathway involving other tests. Cut-off values 
should probably be lower in children.
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objeCtives: The Medical Devices Committee (MDC) of the Maggiore Policlinico 
Hospital in Milan, Italy, approved the use of a minimally invasive insertable cardiac 
monitor (ICM). ICMs are leadless subcutaneous devices that continuously moni-
tor the heart rhythm and record events, allowing for the diagnosis of infrequent 
rhythm abnormalities that can be the cause of palpitations, syncope and stroke. 
Given the limited available literature and foreseen increase in expenditure, the 
MDC established an outcome monitoring process in order to test the effectiveness 
of the device in real practice in detecting abnormal heart rhythms and therefore 
diagnose and implement a timely appropriate treatment. Methods: According 
to the literature, available guidelines and clinical opinion, four groups of patients 
would potentially benefit from the ICM insertion: patients with syncope of unknown 
etiology, myocardial infarction (e.g., arrhythmia risk stratification after the event), 
relapsing arrhythmia after transcatheter ablation of atrial fibrillation (AF) and cryp-
togenic stroke. A standardized data collection form was developed for requesting 
the device to the hospital pharmacy, including patient’s characteristics and clinical 
condition for use. A follow up report describing clinical outcomes (e.g. detected 
arrhythmias, time to event, diagnostic formulation) needs to be provided every 6 
months. Results: From 7/2014 to 5/2015, the ICM was implanted in 14 patients. 
The average patients’ age at the time of insertion was 54,8 years (range: 27-84 years). 
78,6% of patients-(11) showed syncope of unknown etiology, 14,2%(2) suffered a 
cryptogenic stroke, while 1 patient-(7,1%) received transcatheter ablation of AF with 
possible anticoagulant antiarrhythmic therapy suspension. A final diagnosis was 
reached for 5(36%) patients; in particular, for 2 a sustained arrhythmia was detected 
within 15 days since the implant. ConClusions: The inclusion in clinical practice 
of a new technology has increased the expenditure for medical devices. However, the 
forthcoming availability of clinical outcomes will document whether the diagnosis 
process has been improved.
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objeCtives: To determine the published frequency of diagnostic discordance 
leading to potential mismanagement of patient treatment for lymphoma by meta-
analysis. Methods: A systematic literature search using PubMed database was 
conducted from 2000 to May 2015. Literature was restricted to articles published 
after 2000, the year the World Health Organization classification of hematologic 
malignancies was published. The search string used was: ((((((patholog*) OR diag-
